Research
Hormonal
Gut dysbiosis, characterized by reduced bacterial diversity and butyrate production, contributes to the pathogenesis of liver diseases (NAFLD, NASH, Alcoholic Liver Disease, PSC) through the translocation of bacterial products (endotoxins) to the liver, triggering inflammation.
Maintaining gut barrier integrity and microbial diversity is crucial for liver health. Probiotics and dietary fiber may help reduce liver inflammation by preventing the translocation of bacterial endotoxins to the liver.
GoodSupportsHIGH confidence
The liver receives 70% of its blood supply from the intestine via the portal vein, thus it is continually exposed to gut-derived factors including bacterial components, endotoxins... Patients with NAFLD also have increased gut permeability suggesting that translocation of bacteria or microbe derived products into the portal circulation contributes to the pathogenesis.
Why this rating
Strong observational and animal model evidence, with some clinical trial support for probiotics.
Source
The gut microbiota and host health: a new clinical frontier
Julian R. Marchesi et al. · Gut · 2015
DOI 10.1136/gutjnl-2015-309990
narrative_reviewCited 2,301×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Faecal Microbiota Transplantation (FMT) from lean donors to individuals with metabolic syndrome can significantly increase insulin sensitivity and butyrate production, establishing a causal link between microbiota composition and host glucose homeostasis.Good
- Dietary modulation of the gut microbiota, specifically through the intake of prebiotics, probiotics, and polyphenols, can alter microbial composition and metabolic activity to confer health benefits, although human clinical efficacy remains ambiguous compared to animal models.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →